Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair

Liu,Jifang; Hou,Min; Yuan,Taize; Yi,Gao; Zhang,Shuxu; Shao,Xunfan; Chen,Jinhui; Jia,Xiaoting; He,Zhimin

doi:10.3892/or.2012.1932

Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair

Authors:
- Jifang Liu
- Min Hou
- Taize Yuan
- Gao Yi
- Shuxu Zhang
- Xunfan Shao
- Jinhui Chen
- Xiaoting Jia
- Zhimin He
View Affiliations

Affiliations: Cancer Research Institute and Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China, Department of Radiotherapy, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China, Intensive Care Unit, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China, Department of Food and Drug, Qingyuan Polytechnic, Qingyuan, Guangdong 511515, P.R. China
Published online on: July 25, 2012 https://doi.org/10.3892/or.2012.1932
Pages: 1406-1412

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metformin, one of the most widely used antidiabetic drugs, has recently been associated with potential antitumorigenic effects. In this study, we evaluated the possible cytotoxic impact of combined low doses of metformin and ionizing radiation (IR) on 2 human hepatoma cell lines. The cytotoxic effect of metformin combined with IR was subsequently determined by clonogenic survival and cell cycle assays, assessment of mitochondrial complex I and lactate dehydrogenase (LDH) activity, measurement of cellular adenosine triphosphate (ATP) levels, comet assay and analyses of the formation and disappearance of phosphorylated histone H2AX (γ-H2AX) protein. The combination of metformin and IR caused a much stronger cytotoxicity than the treatment with metformin or IR alone, leading to an ~80% decrease in cell viability and ~35% increase in the accumulation of cells in the G2/M phase of the cell cycle in the 2 hepatoma cell lines. In addition, a reduction in mitochondrial complex I activity (~70%) and a significant increase in LDH activity, as well as lactate production were observed in the cells exposed to metformin. Interestingly, a severe depletion in ATP, increased olive tail moment and the delayed disappearance of γ-H2AX expression were detected in the hepatoma cells treated by metformin plus IR. These findings show that the combination of a low concentration of metformin and IR results in the considerable enhancement of cytotoxic effects in human hepatoma cell lines, leading to decreased DNA repair by reducing ATP production. The data provided in this study may elucidate the remarkable efficiency of this combination treatment and suggest that metformin may be used as a potential adjunct to the radiotherapy of hepatocellular carcinoma.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB, Davila JA, Petersen NJ and McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
3	Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS and Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 53:810–821. 2002. View Article : Google Scholar : PubMed/NCBI
4	Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C and Merle P: Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 66:1152–1158. 2006. View Article : Google Scholar
5	Girard N and Mornex F: External radiotherapy for hepatocellular carcinoma. Cancer Radiother. 15:49–53. 2011. View Article : Google Scholar : PubMed/NCBI
6	Liang SX, Zhu XD, Lu HJ, et al: Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer. 103:2181–2188. 2005. View Article : Google Scholar : PubMed/NCBI
7	Diamanti-Kandarakis E, Economou F, Palimeri S and Christakou C: Metformin in polycystic ovary syndrome. Ann NY Acad Sci. 1205:192–198. 2010. View Article : Google Scholar
8	Bianchi C, Penno G, Romero F, Del Prato S and Miccoli R: Treating the metabolic syndrome. Expert Rev Cardiovasc Ther. 5:491–506. 2007. View Article : Google Scholar
9	Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kourelis TV and Siegel RD: Metformin and cancer: new applications for an old drug. Med Oncol. 29:1314–1327. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tennant DA, Durán RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 10:267–277. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
13	Zakikhani M, Dowling RJ, Sonenberg N and Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar : PubMed/NCBI
14	Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hardie DG: Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harb Symp Quant Biol. 76:155–164. 2011. View Article : Google Scholar
16	Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007. View Article : Google Scholar : PubMed/NCBI
17	Hou M, Venier N, Sugar L, et al: Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun. 397:537–542. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hassan MM, Curley SA, Li D, et al: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 116:1938–1946. 2010. View Article : Google Scholar : PubMed/NCBI
19	Lalau JD and Race JM: Lactic acidosis in metformin therapy. Drugs. 1:55–60. 1999. View Article : Google Scholar
20	Vanderlinde RE: Measurement of total lactate dehydrogenase activity. Ann Clin Lab Sci. 15:13–31. 1985.PubMed/NCBI
21	van Dyk E and Pretorius PJ: DNA damage and repair in mammalian cells exposed to p-hydroxyphenylpyruvic acid. Biochem Biophys Res Commun. 338:815–819. 2005.PubMed/NCBI
22	Gu YX, Fan SS, Xiong Y, et al: Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 585:881–887. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I and Cuezva JM: Glucose avidity of carcinomas. Cancer Lett. 276:125–135. 2009. View Article : Google Scholar : PubMed/NCBI
24	Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sanli T, Rashid A, Liu C, et al: Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys. 78:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kinner A, Wu W, Staudt C and Iliakis G: Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008. View Article : Google Scholar : PubMed/NCBI
27	Judit PB, Susan HM and Peggy LO: Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 64:7144–7149. 2004. View Article : Google Scholar : PubMed/NCBI
28	Klokov D, MacPhail SM, Banáth JP, Byrne JP and Olive PL: Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol. 80:223–229. 2006. View Article : Google Scholar : PubMed/NCBI
29	Raju U, Nakata E, Yang P, Newman RA, Ang KK and Milas L: In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys. 54:886–894. 2002. View Article : Google Scholar : PubMed/NCBI
30	Huang G, Wang H and Yang LX: Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res. 30:937–944. 2010.PubMed/NCBI
31	Petermann E, Ziegler M and Oei SL: ATP-dependent selection between single nucleotide and long patch base excision repair. DNA Repair. 2:1101–1114. 2003. View Article : Google Scholar : PubMed/NCBI
32	Lammens K, Bemeleit DJ, Mockel C, et al: The Mre11:Rad50 structure shows an ATP-dependent molecular clamp in DNA double-strand break repair. Cell. 145:54–66. 2011. View Article : Google Scholar : PubMed/NCBI
33	Lyamzaev KG, Izyumov DS and Avetisyan AV: Inhibition of mitochondrial bioenergetics: the effects on structure of mitochondria in the cell and on apoptosis. Acta Biochim Pol. 51:553–562. 2004.PubMed/NCBI
34	Halicka HD, Zhao H, Li JW, Traganos1 F, Zhang SF, Lee M and Darzynkiewicz1 Z: Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging. 3:1–11. 2011.PubMed/NCBI
35	Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 69:6539–6545. 2009. View Article : Google Scholar : PubMed/NCBI
37	Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.PubMed/NCBI
38	Algire C, Zakikhani M, Blouin MJ, Shuai JH and Pollak M: Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 15:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
39	Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar : PubMed/NCBI
40	Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 30:359–371. 1996. View Article : Google Scholar : PubMed/NCBI
41	Isoda K, Young JL, Zirlik A, et al: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 26:611–617. 2006. View Article : Google Scholar : PubMed/NCBI
42	Graham GG, Punt J, Arora M, et al: Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI